Abstract
Background and Aims Ulcerative colitis (UC) with concomitant primary sclerosing cholangitis (PSC) represents a distinct disease entity (PSC-UC). Mayo endoscopic subscore (MES) is a standard tool for assessing disease activity in UC but its relevance in PSC-UC remains unclear. Here, we sought to compare MES in a cohort of UC and PSC-UC patients and assess the accuracy using histological activity scoring (Nancy histological index; NHI).
Methods MES was assessed in 30 PSC-UC and 29 UC adult patients during endoscopy. NHI and inflammation were evaluated in biopsies from the caecum, rectum, and terminal ileum. In addition, perinuclear anti-neutrophil cytoplasmic antibodies, fecal calprotectin, body mass index, and other relevant clinical characteristics were collected.
Results The median MES and NHI were similar for UC patients (MES grade 2 and NHI grade 2 in the rectum), but were different for PSC-UC patients (MES grade 0 and NHI grade 2 in the caecum). There was a correlation between MES and NHI for UC patients (Spearman’s ρ = 0.40, p = 0.029), but not for PSC-UC patients. Histopathological examination revealed persistent microscopic inflammation in 88% of PSC-UC patients with MES grade 0 (46% of all PSC-UC patients). Moreover, MES overestimated the severity of active inflammation in another 11% of PSC-UC patients.
Conclusion MES fails to identify microscopic signs of inflammation in the context of PSC-UC. This indicates that histological evaluation should become an integral part of the diagnostic and grading system in both PSC-UC and PSC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the Grant Agency of the Ministry of Health of the Czech Republic [NV17-31538A to M.G. and Pa.W.], the Grant Agency of the Czech Republic [20-16520Y to A.K. and 21-21736S to M.G.], and the Ministry of Education, Youth and Sports of the Czech Republic project NICR EXCELES [LX22NPO05102 to M.G.].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics Committee of the Institute for Clinical and Experimental Medicine and Thomayer Hospital with Multi-Center Competence waived ethical approval for this work (G16-06-25).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data underlying this article cannot be shared publicly due to the privacy of individuals that participated in this study. The data will be shared on reasonable request to the corresponding authors.
